Algen Biotechnologies

Executive Summary

Algen Biotechnologies is a privately held, early-stage biotechnology company based in San Diego, California, leveraging CRISPR-based discoveries from Nobel Laureate Jennifer Doudna’s lab combined with artificial intelligence and machine learning to discover novel therapeutics for diseases with high unmet medical needs. Founded in 2018, the company aims to revolutionize drug discovery by integrating cutting-edge gene-editing platforms with computational biology, potentially enabling precision medicines for challenging indications. While financial details and clinical stage remain undisclosed, Algen’s approach—rooted in world-class science—positions it to address significant gaps in areas such as genetic disorders, oncology, and rare diseases. The company operates at the intersection of two high-impact sectors: genetics/genomics and AI/machine learning, which may attract strategic partnerships and investor interest as it advances its pipeline toward preclinical and clinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Announcement60% success
• Q4 2026Lead Program Nomination or Preclinical Data Readout50% success
• Q3 2026Academic or Industry Partnership Disclosure55% success